LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Search

Ligand Pharmaceuticals Inc

Closed

SectorHealthcare

200.01 -0.21

Overview

Share price change

24h

Current

Min

197.8

Max

207.35

Key metrics

By Trading Economics

Income

47M

4.8M

Sales

70M

115M

P/E

Sector Avg

92.606

105.69

Profit margin

4.198

Employees

68

EBITDA

103M

62M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+18.65% upside

Market Stats

By TradingEconomics

Market Cap

1.5B

4.1B

Previous open

200.22

Previous close

200.01

News Sentiment

By Acuity

28%

72%

70 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 lis 2025, 18:59 UTC

Major Market Movers

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17 lis 2025, 23:40 UTC

Market Talk

Gold Consolidates Amid Mixed Signals -- Market Talk

17 lis 2025, 23:34 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17 lis 2025, 22:58 UTC

Market Talk

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17 lis 2025, 22:46 UTC

Market Talk

Risk Assets Set to Have a Strong 2026 -- Market Talk

17 lis 2025, 22:06 UTC

Acquisitions, Mergers, Takeovers

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17 lis 2025, 22:02 UTC

Earnings

Trip.com Group 3Q Rev $2.6B >TCOM

17 lis 2025, 22:02 UTC

Earnings

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17 lis 2025, 22:02 UTC

Earnings

Trip.com Group 3Q EPS $4.02 >TCOM

17 lis 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 lis 2025, 21:40 UTC

Earnings

James Hardie Industries 2Q Adj EPS 26c >JHX

17 lis 2025, 21:40 UTC

Earnings

James Hardie Industries 2Q Loss/Shr 10c >JHX

17 lis 2025, 21:39 UTC

Earnings

James Hardie Industries 2Q Sales $1.29B >JHX

17 lis 2025, 21:38 UTC

Earnings
Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 lis 2025, 21:38 UTC

Earnings

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17 lis 2025, 21:10 UTC

Earnings

XP Inc. 3Q EPS BRL2.47 >XP

17 lis 2025, 21:10 UTC

Earnings

XP Inc. 3Q Rev BRL4.67B >XP

17 lis 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17 lis 2025, 20:12 UTC

Market Talk

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17 lis 2025, 20:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 lis 2025, 20:09 UTC

Market Talk

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17 lis 2025, 19:29 UTC

Market Talk

Gold Slide Continues to Start Week -- Market Talk

17 lis 2025, 19:16 UTC

Earnings
Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 lis 2025, 18:20 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17 lis 2025, 16:45 UTC

Acquisitions, Mergers, Takeovers

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17 lis 2025, 16:16 UTC

Earnings
Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 lis 2025, 16:15 UTC

Earnings

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17 lis 2025, 15:40 UTC

Acquisitions, Mergers, Takeovers

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17 lis 2025, 15:22 UTC

Acquisitions, Mergers, Takeovers

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17 lis 2025, 15:19 UTC

Market Talk

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Peer Comparison

Price change

Ligand Pharmaceuticals Inc Forecast

Price Target

By TipRanks

18.65% upside

12 Months Forecast

Average 238.33 USD  18.65%

High 275 USD

Low 220 USD

Based on 6 Wall Street analysts offering 12 month price targets forLigand Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

102.5 / 109.24Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Very Strong Bearish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

70 / 374 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
help-icon Live chat